Evidence map›Paper›PMID 32893494›Full record

ReviewAdvanced healthcare materials2021

Microfluidic Biomaterials.

Joe Tien, Yoseph W Dance

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Hydrogel applications: a promising frontier in pneumonia therapy.Frontiers in bioengineering and biotechnology · 2025
    Review
  5. Application and progress of 3D printed biomaterials in osteoporosis.Frontiers in bioengineering and biotechnology · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Engineered biomimetic micro/nano-materials for tissue regeneration.Frontiers in bioengineering and biotechnology · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joe TienDepartment of Biomedical Engineering, Boston University, Boston, MA, 02215, USA.ORCID 0000-0003-4283-3986
Yoseph W DanceDepartment of Biomedical Engineering, Boston University, Boston, MA, 02215, USA.

Funding

TRAINING PROGRAM IN QUANTITATIVE BIOLOGY AND PHYSIOLOGYT32GM008764 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WHITE, JOHN A. · 2001 to 2021
$5.9M
Engineered Invasive Human Breast Tumors with Integrated Capillaries and LymphaticsU01CA214292 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI NELSON, CELESTE M, TIEN, JOE Y · 2017 to 2021
$3.2M
NCI NIH HHS U01 CA214292NIGMS NIH HHS T32 GM008764
6 · The paper itself

Abstract

Since their initial description in 2005, biomaterials that are patterned to contain microfluidic networks ("microfluidic biomaterials") have emerged as promising scaffolds for a variety of tissue engineering and related applications. This class of materials is characterized by the ability to be readily perfused. Transport and exchange of solutes within microfluidic biomaterials is governed by convection within channels and diffusion between channels and the biomaterial bulk. Numerous strategies have been developed for creating microfluidic biomaterials, including micromolding, photopatterning, and 3D printing. In turn, these materials have been used in many applications that benefit from the ability to perfuse a scaffold, including the engineering of blood and lymphatic microvessels, epithelial tubes, and cell-laden tissues. This article reviews the current state of the field and suggests new areas of exploration for this unique class of materials.

Indexed as

Biocompatible MaterialsTissue ScaffoldsHydrogelsMicrofluidicsPrinting, Three-DimensionalTissue EngineeringBiocompatible MaterialsHydrogelscollagenhydrogelsmicrophysiological systemsmicrovascular tissue engineeringperfusion

Identifiers

PMID32893494
PMCPMC7889648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.